Date	e:August 16, 2021		
You	r Name:Henry LY Ch	nan	
Mar	uscript Title: Targeted Long	-Read Sequencing Reveals	Clonally Expanded HBV-Associated
Chro	omosomal Translocations in	CHB Patients	
Mar	nuscript number (if known):		
relat part to tr	ted to the content of your miles whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th	•	nsion, you should declare a	efined broadly. For example, if your manuscript pertains II relationships with manufacturers of antihypertensive e manuscript.
	em #1 below, report all supplitime frame for disclosure is	•	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	This study was funded by	
	manuscript (e.g., funding,	Gilead Sciences	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		

Time frame: past 36 months

\_\_\_\_ None

None

Grants or contracts from

in item #1 above).

Royalties or licenses

3

any entity (if not indicated

4	Consulting fees	Advisor of Gilead	Personal honorarium
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
	, , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or pending	None	
		.,	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
42	D	N.	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
12	Services Other financial or non	Nana	
13	Other financial or non- financial interests	None	

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:11/30/2021	
Your Name:Becket Feierbach	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _X None	36 months
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
_	D	N N	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Compart for attending	Nene	These presented this work at EACL 2021 and rev
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Loadorship or fiducion, rolo	V None	
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	As an employee of Gilead Sciences, I have received and
	Stock of Stock options	Gilead Sciences Inc	still own Restricted Stock Units
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
12	services Other financial or non-	V None	
13	financial interests	_X None	

Date:11/30/2021	
Your Name:Dong Han	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.2	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Hongmei Mo	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHR Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name: Li Li	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past _X NoneX None	36 months

4	Consulting fees	_X None	
-	December to be a service for	V None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	_X None	
7	Support for attending	None	I have presented this work at EASL 2021 and my
,	meetings and/or travel		attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
0	Participation on a Data	V None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	_X None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	As an ampleyee of Cilead Sciences They received and
11	Stock of Stock options	Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
13	services Other financial or non-	_X None	
13	financial interests	_X None	

Date:11,	30/2021
Your Name:	Maria Buti
Manuscript Title:_	Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated
Chromosomal Tra	nslocations in CHB Patients
Manuscript numb	er (if known):
related to the con	ransparency, we ask you to disclose all relationships/activities/interests listed below that are tent of your manuscript. "Related" means any relation with for-profit or not-for-profit third

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	Gilead Abbvie	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead Abbvie	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
13	services Other financial or non-	None	
13	financial interests	None	

Х

form.

Date:11/30/2021	
Your Name:Ross Martin	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.0	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Lindsey May	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.2	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Nam Bui	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.0	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:	11/30/2021
-------	------------

Your Name: Neeru Bhardwaj

Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated Chromosomal

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	Was previously employed at Gilead (2015-2018)
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	X None	
	in item #1 above).		
3	Royalties or licenses	X None	

4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	X None	
_			
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	Received company stock while an employee at Gilead
40			
12	Receipt of equipment, materials, drugs, medical	X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	X None	

Date:11/30/2021	
Your Name:PC Parvangada	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.2	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Ricardo Ramirez	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past _X NoneX None	36 months

4	Consulting fees	_X None	
-	December to be a service for	V None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	_X None	
7	Support for attending	None	I have presented this work at EASL 2021 and my
,	meetings and/or travel		attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
0	Participation on a Data	V None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	_X None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	As an ampleyee of Cilead Sciences They received and
11	Stock of Stock options	Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
13	services Other financial or non-	_X None	
13	financial interests	_X None	

Date:11/30/2021	
Your Name:Cameron Soulette	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.2	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Scott Turner	
Manuscript Title: : Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _X None	36 months
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
-	December to be a service for	V None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	_X None	
7	Support for attending	None	I have presented this work at EASL 2021 and my
,	meetings and/or travel		attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
0	Participation on a Data	V None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	_X None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	As an ampleyee of Cilead Sciences They received and
11	Stock of Stock options	Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
13	services Other financial or non-	_X None	
13	financial interests	_X None	

Date:11/30/2021	
Your Name:Vithika Suri	
Manuscript Title: : Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.0	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Nick van Buuren	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Gilead Sciences Inc	I am a current employee of Gilead Sciences Inc. The research was funded whole by Gilead Sciences Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None	
5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	None	I have presented this work at EASL 2021 and my attendance was funded by Gilead Sciences Inc.
		Gilead Sciences Inc	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None Gilead Sciences Inc	As an employee of Gilead Sciences, I have received and still own Restricted Stock Units
4.0	D	V N	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_X None	

Date:11/30/2021	
Your Name:Anuj Gaggar	
Manuscript Title: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T		planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	Gilead Sciences	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	None	
		Gilead Sciences	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or	Gilead Sciences	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,	HBV Forum	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
		Gilead Sciences	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	Services Other financial or non	V None	
13	Other financial or non- financial interests	XNone	
	imancial interests		

Date:11/30/2021	
Your Name: Patrick Marcellin	
Manuscript Title: _: Targeted Long-Read Sequencing Reveals Clonally Expanded HBV-Associated	
Chromosomal Translocations in CHB Patients	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Gilead	We helped collect the Biopsies at our site
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	g .		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N .	
11	Stock or stock options	None	
12	Descipt of a minus ant	N	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		